Menü

Publikationsliste

Authors Jugel, W. ; Aigner, A. ; Michen, S. ; Hagstotz, A. ; Ewe, A. ; Appelhans, D. ; Schackert, G. ; Temme, A. ; Tietze, S.
Title Targeted RNAi of BIRC5/survivin using antibody-conjugated poly(propylene imine)-based polyplexes inhibits growth of PSCA-positive tumors
Date 27.08.2021
Number 59265
Abstract Delivery of siRNAs for the treatment of tumors critically depends on the development of efficient nucleic acid carrier systems. The complexation of dendritic polymers (dendrimers) results in nanoparticles, called dendriplexes, that protect siRNA from degradation and mediate non-specific cellular uptake of siRNA. However, large siRNA doses are required for in vivo use due to accumulation of the nanoparticles in sinks such as the lung, liver, and spleen. This suggests the exploration of targeted nanoparticles for enhancing tumor cell specificity and achieving higher siRNA levels in tumors. In this work, we report on the targeted delivery of a therapeutic siRNA specific for BIRC5/Survivin in vitro and in vivo to tumor cells expressing the surface marker prostate stem cell antigen (PSCA). For this, polyplexes consisting of single-chain antibody fragments specific for PSCA conjugated to siRNA/maltose-modified poly(propylene imine) dendriplexes were used. These polyplexes were endocytosed by PSCA-positive 293TPSCA/ffLuc and PC3PSCA cells and caused knockdown of reporter gene firefly luciferase and Survivin expression, respectively. In a therapeutic study in PC3PSCA xenograft-bearing mice, significant anti-tumor effects were observed upon systemic administration of the targeted polyplexes. This indicates superior anti-tumor efficacy when employing targeted delivery of Survivin-specific siRNA, based on the additive effects of siRNA-mediated Survivin knockdown in combination with scFv-mediated PSCA inhibition.
Journal Pharmaceutics
Wikidata
Citation Pharmaceutics 13 (2021) 676
DOI https://doi.org/10.3390/PHARMACEUTICS13050676

Back to list